Pay in 4 interest-free payments of $6.64 Learn more
Ships within 48 hours · Estimated delivery Sep 3 - Sep 8
The largest Phase 2b trial (502 participants, 24 weeks) did not show statistically significant weight loss versus placebo
While serious side effects are uncommon, patients should immediately report any concerning symptoms to their healthcare provider
Early Phase (Days 1-7) Anti-inflammatory effects may manifest within the first 1-3 days as the peptide begins modulating inflammatory mediators
WADA includes BPC-157 on its Prohibited List under category S0 (non-approved substances), which covers any substance not approved by a regulatory authority for human therapeutic use
Follow the product label and any lot-specific documentation
By modulating this pathway, researchers explore how it may support investigations into metabolic energy balance, adipose response, and overall metabolic health
US$ 22.14
US$ 27.71
US$ 23.55
US$ 21.15
